TG Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on July 28, 2023, by TG Therapeutics, Inc. (TGTX), a Delaware corporation. The filing primarily reports the entry into a material definitive agreement on July 28, 2023, and references the issuance of a press release on August 1, 2023, regarding financial results for the three and six months ended June 30, 2023.
Key Financial Metrics and Deal Terms
The filing details a Commercialization Agreement with Neuraxpharm Pharmaceuticals, S.L. for the exclusive license to commercialize BRIUMVI (ublituximab) for relapsing forms of multiple sclerosis in Europe and certain other territories (excluding Canada, Mexico, and certain Asian countries). Key financial terms include:
- Upfront Payment: $140 million in cash.
- Launch Payment: $12.5 million upon commercial launch in the first European country.
- Milestone Payments: Up to $492.5 million contingent on launch and commercial milestones.
- Total Deal Value: Up to $645 million in upfront and milestone payments.
- Royalties: Tiered double-digit royalties on net product sales, up to 30%.
The filing references a press release for the three and six months ended June 30, 2023, but does not contain specific revenue, profit, cash flow, margin, debt, or liquidity figures within the text of this 8-K.
Material Changes and Agreements
The primary material change is the execution of the Commercialization Agreement with Neuraxpharm. Under this agreement:
- Neuraxpharm is obligated to use commercially reasonable efforts to launch and commercialize BRIUMVI in the designated Territory.
- TG Therapeutics retains an option to buy back all rights for approximately two years in the event of a change in control.
- TG Therapeutics will supply BRIUMVI to Neuraxpharm via a third-party manufacturer under a Master Services Agreement.
Outlook, Risks, and Contingencies
Termination Rights: The agreement may be terminated for uncured material breach, insolvency, or bankruptcy. TG Therapeutics may also terminate if Neuraxpharm challenges patents, fails to meet minimum sales targets, or if a change of control occurs within two years.
Regulatory Status: The agreement is expected to be filed as an exhibit to the Quarterly Report on Form 10-Q for the quarter ended June 30, 2023. The financial results referenced in Item 2.02 are not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the specific financial results for the three and six months ended June 30, 2023, in the referenced press release (Exhibit 99.1) or the upcoming Form 10-Q, as this 8-K does not list specific revenue or cash flow numbers.
- Review the full text of the Commercialization Agreement and Master Services Agreement once filed as exhibits to the Form 10-Q for detailed terms on supply obligations and royalty tiers.
- Monitor the achievement of the $12.5 million launch milestone and subsequent commercial milestones to assess the realization of the $645 million total deal value.
- Confirm the status of marketing authorizations for BRIUMVI in the European Territory to evaluate the timeline for commercial launch.